Enliven Therapeutics Faces Headwinds ELVN Drops 285 Amid Biotech Volatility Nationwide Customer Challenges Lenders Unfair Treatment in Board Election Bid QNRX Q1 2026 Earnings Narrowed Loss Per Share Exceeds Estimates Retail Sales Rise Solidly but Early Signs of Consumer Spending Pullback Emerge